1887
Research article Open Access
Like 0

Abstract

As elsewhere, few (< 15%) sentinel influenza A(H3N2) clade 3C.2a viruses that dominated in Canada during the 2014/15 season could be antigenically characterised by haemagglutination inhibition (HI) assay. Clade 3C.2a viruses that could be HI-characterised had acquired genetic mutations during in vitro cell culture isolation that modified the potential glycosylation motif found in original patient specimens and the consensus sequence of circulating viruses at amino acid positions 158–160 of the haemagglutinin protein. Caution is warranted in extrapolating antigenic relatedness based on limited HI findings for clade 3C.2a viruses that continue to circulate globally.

Loading

Article metrics loading...

/content/10.2807/1560-7917.ES.2016.21.3.30112
2016-01-21
2017-11-25
http://instance.metastore.ingenta.com/content/10.2807/1560-7917.ES.2016.21.3.30112
Loading
Loading full text...

Full text loading...

/deliver/fulltext/eurosurveillance/21/3/eurosurv-21-30112-2.html?itemId=/content/10.2807/1560-7917.ES.2016.21.3.30112&mimeType=html&fmt=ahah

References

  1. European Centre for Disease Prevention and Control (ECDC). Influenza virus characterisation. Summary Europe, September 2015. Stockholm: ECDC; 2015. Available from: http://ecdc.europa.eu/en/publications/Publications/influenza-virus-characterisation-september-2015.pdf
  2. Skowronski DM, Chambers C, Sabaiduc S, De Serres G, Dickinson JA, Winter AL, et al. Interim estimates of 2014/15 vaccine effectiveness against influenza A(H3N2) from Canada’s Sentinel Physician Surveillance Network, January 2015. Euro Surveill. 2015;20(4):21022.  https://doi.org/10.2807/1560-7917.ES2015.20.4.21022  PMID: 25655053 
  3. Ndifon W, Wingreen NS, Levin SA. Differential neutralization efficiency of hemagglutinin epitopes, antibody interference, and the design of influenza vaccines. Proc Natl Acad Sci USA. 2009;106(21):8701-6.  https://doi.org/10.1073/pnas.0903427106  PMID: 19439657 
  4. Popova L, Smith K, West AH, Wilson PC, James JA, Thompson LF, et al. Immunodominance of antigenic site B over site A of hemagglutinin of recent H3N2 influenza viruses. PLoS ONE. 2012;7(7):e41895.  https://doi.org/10.1371/journal.pone.0041895  PMID: 22848649 
  5. An Y, McCullers JA, Alymova I, Parsons LM, Cipollo JF. Glycosylation analysis of engineered H3N2 influenza A virus hemagglutinins with sequentially added historically relevant glycosylation sites. J Proteome Res. 2015;14(9):3957-69.  https://doi.org/10.1021/acs.jproteome.5b00416  PMID: 26202417 
  6. Tate MD, Job ER, Deng YM, Gunalan V, Maurer-Stroh S, Reading PC. Playing hide and seek: how glycosylation of the influenza virus hemagglutinin can modulate the immune response to infection. Viruses. 2014;6(3):1294-316.  https://doi.org/10.3390/v6031294  PMID: 24638204 
  7. Koel BF, Burke DF, Bestebroer TM, van der Vliet S, Zondag GC, Vervaet G, et al. Substitutions near the receptor binding site determine major antigenic change during influenza virus evolution. Science. 2013;342(6161):976-9.  https://doi.org/10.1126/science.1244730  PMID: 24264991 
  8. Chambers BS, Parkhouse K, Ross TM, Alby K, Hensley SE. Identification of hemagglutinin residues responsible for H3N2 antigenic drift during the 2014-2015 influenza season. Cell Reports. 2015;12(1):1-6.  https://doi.org/10.1016/j.celrep.2015.06.005  PMID: 26119736 
  9. Flannery B, Clippard J, Zimmerman RK, Nowalk MP, Jackson ML, Jackson LA, et al. Centers for Disease Control and Prevention. Early estimates of seasonal influenza vaccine effectiveness - United States, January 2015. MMWR Morb Mortal Wkly Rep. 2015;64(1):10-5. PMID: 25590680 
  10. Pebody RG, Warburton F, Ellis J, Andrews N, Thompson C, von Wissmann B, et al. Low effectiveness of seasonal influenza vaccine in preventing laboratory-confirmed influenza in primary care in the United Kingdom: 2014/15 mid-season results. Euro Surveill. 2015;20(5):21025.  https://doi.org/10.2807/1560-7917.ES2015.20.5.21025  PMID: 25677050 
  11. World Health Organization (WHO). Recommended composition of influenza virus vaccines for use in the 2015-2016 northern hemisphere influenza season. Geneva: WHO; 2015. [Accessed: 10 Dec 2015]. Available from: http://www.who.int/influenza/vaccines/virus/recommendations/2015_16_north/en/
  12. Smith S, Blanton L, Kniss K, Mustaquim D, Steffens C, Reed C, et al. Update: influenza activity - United States, October 4—November 28, 2015. MMWR Morb Mortal Wkly Rep. 2015;64(48):1342-8.  https://doi.org/10.15585/mmwr.mm6448a4 
  13. Public Health Agency of Canada (PHAC). FluWatch: Weekly influenza reports. Ottawa: PHAC; Available from: http://healthycanadians.gc.ca/publications/diseases-conditions-maladies-affections/fluwatch-2015-2016-51-52-surveillance-influenza/index-eng.php
  14. European Centre for Disease Prevention and Control (ECDC). Influenza virus characterization. Summary Europe, February 2015. Stockholm: ECDC; 2015. Available from: http://ecdc.europa.eu/en/publications/Publications/ERLI-Net-report-February-2015.pdf
  15. Lin YP, Gregory V, Collins P, Kloess J, Wharton S, Cattle N, et al. Neuraminidase receptor binding variants of human influenza A(H3N2) viruses resulting from substitution of aspartic acid 151 in the catalytic site: a role in virus attachment? J Virol. 2010;84(13):6769-81.  https://doi.org/10.1128/JVI.00458-10  PMID: 20410266 
  16. Oh DY, Barr IG, Mosse JA, Laurie KL. MDCK-SIAT1 cells show improved isolation rates for recent human influenza viruses compared to conventional MDCK cells. J Clin Microbiol. 2008;46(7):2189-94.  https://doi.org/10.1128/JCM.00398-08  PMID: 18480230 
  17. Katz JM, Hancock K, Xu X. Serologic assays for influenza surveillance, diagnosis and vaccine evaluation. Expert Rev Anti Infect Ther. 2011;9(6):669-83.  https://doi.org/10.1586/eri.11.51  PMID: 21692672 
  18. World Health Organization. Recommended composition of influenza virus vaccines for use in the 2016 southern hemisphere influenza season. Geneva: WHO; 2015. Available from: http://www.who.int/influenza/vaccines/virus/recommendations/2016_south/en/
  19. Gupta R, Jung E, Brunak S. Prediction of N-glycosylation sites in human proteins. NetNGlyc 1.0. Denmark: Center for Biological Sequence Analysis. [Accessed: 10 Dec 2015]. Available from: http://www.cbs.dtu.dk/services/NetNGlyc/
  20. Lin YP, Xiong X, Wharton SA, Martin SR, Coombs PJ, Vachieri SG, et al. Evolution of the receptor binding properties of the influenza A(H3N2) hemagglutinin. Proc Natl Acad Sci USA. 2012;109(52):21474-9.  https://doi.org/10.1073/pnas.1218841110  PMID: 23236176 
/content/10.2807/1560-7917.ES.2016.21.3.30112
Loading

Data & Media loading...

Comment has been disabled for this content
Submit comment
Close
Comment moderation successfully completed
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error